{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:32:05Z","timestamp":1786707125397,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"DOI":"10.1007\/s13318-026-01024-y","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:52:56Z","timestamp":1786704776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma Carbamazepine and Carbamazepine-Epoxide Concentrations as Indicators of Consciousness Impairment in Acute Poisoning: A Sex-Based Analysis"],"prefix":"10.1007","author":[{"given":"Vladan","family":"Lukic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1743-2830","authenticated-orcid":false,"given":"Aleksandra","family":"Kovacevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Perkovic Vukcevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snezana","family":"Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momir","family":"Mikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktorija","family":"Dragojevic Simi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"5","key":"1024_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526\u201348. https:\/\/doi.org\/10.1097\/FTD.0000000000000546.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"1024_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/096032718300200405","volume":"2","author":"HK Hundt","year":"1983","unstructured":"Hundt HK, Aucamp AK, M\u00fcller FO. Pharmacokinetic aspects of carbamazepine and its two major metabolites in plasma during overdosage. Hum Toxicol. 1983;2(4):607\u201314. https:\/\/doi.org\/10.1177\/096032718300200405.","journal-title":"Hum Toxicol"},{"issue":"7","key":"1024_CR3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia. 2008;49(7):1239\u201376. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01561.x.","journal-title":"Epilepsia"},{"key":"1024_CR4","volume-title":"Metabolism of drugs and selected xenobiotics","author":"S Rendi\u0107","year":"2013","unstructured":"Rendi\u0107 S, Medi\u0107-\u0160ari\u0107 M. Metabolism of drugs and selected xenobiotics. Zagreb: Medicinska naklada; 2013."},{"key":"1024_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/369707","volume":"2015","author":"JL Russell","year":"2015","unstructured":"Russell JL, Spiller HA, Baker DD. Markedly elevated carbamazepine-10,11-epoxide\/carbamazepine ratio in a fatal carbamazepine ingestion. Case Rep Med. 2015;2015:369707. https:\/\/doi.org\/10.1155\/2015\/369707.","journal-title":"Case Rep Med."},{"issue":"2","key":"1024_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.arcmed.2003.09.016","volume":"35","author":"J Moreno","year":"2004","unstructured":"Moreno J, Belmont A, Jaimes O, Santos JA, L\u00f3pez G, Campos MG, et al. Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. Arch Med Res. 2004;35(2):168\u201371. https:\/\/doi.org\/10.1016\/j.arcmed.2003.09.016.","journal-title":"Arch Med Res"},{"issue":"3","key":"1024_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/BF00936891","volume":"242","author":"S Schmidt","year":"1995","unstructured":"Schmidt S, Schmitz-Buhl M. Signs and symptoms of carbamazepine overdose. J Neurol. 1995;242(3):169\u201373. https:\/\/doi.org\/10.1007\/BF00936891.","journal-title":"J Neurol"},{"issue":"5","key":"1024_CR8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1212\/wnl.38.5.755","volume":"38","author":"DF Weaver","year":"1988","unstructured":"Weaver DF, Camfield P, Fraser A. Massive carbamazepine overdose: clinical and pharmacologic observations in five episodes. Neurology. 1988;38(5):755\u20139. https:\/\/doi.org\/10.1212\/wnl.38.5.755.","journal-title":"Neurology"},{"issue":"3","key":"1024_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","volume":"48","author":"OP Soldin","year":"2009","unstructured":"Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143\u201357. https:\/\/doi.org\/10.2165\/00003088-200948030-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1024_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32. https:\/\/doi.org\/10.1186\/s13293-020-00308-5.","journal-title":"Biol Sex Differ"},{"key":"1024_CR11","unstructured":"Medicine and Medical Devices Agency of Serbia. Search of medicines and medical devices. [cited 2025 May 20]. Available from: https:\/\/www.alims.gov.rs\/english"},{"issue":"8","key":"1024_CR12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S1474-4422(14)70120-6","volume":"13","author":"G Teasdale","year":"2014","unstructured":"Teasdale G, Maas A, Lecky F, Manley G, Stocchetti N, Murray G. The Glasgow Coma Scale at 40 years: standing the test of time. Lancet Neurol. 2014;13(8):844\u201354. https:\/\/doi.org\/10.1016\/S1474-4422(14)70120-6. (Erratum in: Lancet Neurol. 2014 Sep;13(9):863.).","journal-title":"Lancet Neurol"},{"issue":"8","key":"1024_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/17425255.2024.2381555","volume":"20","author":"V Lukic","year":"2024","unstructured":"Lukic V, Jankovic SM, Petrovic NZ, Vucinic S, Jovic Stosic J, Djordjevic S, et al. Population toxicokinetics of carbamazepine and its metabolite carbamazepine-10,11-epoxide in adults. Expert Opin Drug Metab Toxicol. 2024;20(8):817\u201325. https:\/\/doi.org\/10.1080\/17425255.2024.2381555.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"1024_CR14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149\u201360.","journal-title":"Behav Res Methods"},{"issue":"4","key":"1024_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3109\/15563659509028916","volume":"33","author":"VL Montgomery","year":"1995","unstructured":"Montgomery VL, Richman BJ, Goldsmith LJ, Rodgers GC Jr. Severity and carbamazepine level at time of initial poison center contact correlate with outcome in carbamazepine poisoning. J Toxicol Clin Toxicol. 1995;33(4):311\u201323. https:\/\/doi.org\/10.3109\/15563659509028916.","journal-title":"J Toxicol Clin Toxicol"},{"issue":"3","key":"1024_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00003088-198611030-00001","volume":"11","author":"L Bertilsson","year":"1986","unstructured":"Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokinet. 1986;11(3):177\u201398.","journal-title":"Clin Pharmacokinet."},{"issue":"10","key":"1024_CR17","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1002\/ccr3.1118","volume":"5","author":"K Karaman","year":"2017","unstructured":"Karaman K, T\u00fcrkdo\u011fan KA, Deniz AT, \u00c7anak\u00e7\u0131 SE. Which is the best in carbamazepine overdose? Clin Case Rep. 2017;5(10):1612\u20135. https:\/\/doi.org\/10.1002\/ccr3.1118.","journal-title":"Clin Case Rep"},{"issue":"2","key":"1024_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2165\/00003495-199550020-00003","volume":"50","author":"RZ Harris","year":"1995","unstructured":"Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50(2):222\u201339.","journal-title":"Drugs"},{"key":"1024_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7742(08)00001-9","volume":"83","author":"GD Anderson","year":"2008","unstructured":"Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008;83:1\u201310. https:\/\/doi.org\/10.1016\/S0074-7742(08)00001-9. (PMID: 18929073).","journal-title":"Int Rev Neurobiol."},{"issue":"3","key":"1024_CR20","doi-asserted-by":"publisher","first-page":"1000119","DOI":"10.4172\/2157-7609.1000119","volume":"3","author":"L Yang","year":"2012","unstructured":"Yang L, Li Y, Hong H, Chang C, Guo L, Lyn-Cook B, et al. Sex differences in the expression of drug-metabolizing and transporter genes in human liver. J Drug Metab Toxicol. 2012;3(3):1000119.","journal-title":"J Drug Metab Toxicol."},{"issue":"3","key":"1024_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1248\/jhs.55.325","volume":"55","author":"T Sakuma","year":"2009","unstructured":"Sakuma T, Kawasaki Y, Jarukamjorn K, Nemoto N. Sex differences of drug-metabolizing enzyme: female predominant expression of human and mouse cytochrome P450 3A isoforms. J Health Sci. 2009;55(3):325\u201337.","journal-title":"J Health Sci"},{"key":"1024_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.05.014","volume":"175","author":"MC Madla","year":"2021","unstructured":"Madla MC, Gavins FKH, Merchant HA, Orlu M, Murdan S, Basit AW. Let\u2019s talk about sex: differences in drug therapy in males and females. Adv Drug Deliv Rev. 2021;175:113804.","journal-title":"Adv Drug Deliv Rev."},{"issue":"2","key":"1024_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0022-3565(25)12089-2","volume":"275","author":"EG Schuetz","year":"1995","unstructured":"Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther. 1995;275(2):1011\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1024_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1124\/mol.109.056705","volume":"76","author":"DJ Waxman","year":"2009","unstructured":"Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol. 2009;76(2):215\u201328. https:\/\/doi.org\/10.1124\/mol.109.056705.","journal-title":"Mol Pharmacol"},{"issue":"6","key":"1024_CR25","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/j.1528-1157.1994.tb01793.x","volume":"35","author":"H Liu","year":"1994","unstructured":"Liu H, Delgado MR. A comprehensive study of the relation between serum concentrations, concentration ratios, and level\/dose ratios of carbamazepine and its metabolites with age, weight, dose, and clearances in epileptic children. Epilepsia. 1994;35(6):1221\u20139. https:\/\/doi.org\/10.1111\/j.1528-1157.1994.tb01793.x.","journal-title":"Epilepsia"},{"issue":"2","key":"1024_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020270","volume":"13","author":"LM Fuhr","year":"2021","unstructured":"Fuhr LM, Marok FZ, Hanke N, Selzer D, Lehr T. Pharmacokinetics of the CYP3A4 and CYP2B6 inducer carbamazepine and its drug-drug interaction potential: a physiologically based pharmacokinetic modeling approach. Pharmaceutics. 2021;13(2):270. https:\/\/doi.org\/10.3390\/pharmaceutics13020270.","journal-title":"Pharmaceutics"},{"key":"1024_CR27","first-page":"698","volume-title":"Goldfrank\u2019s toxicologic emergencies","author":"S Doyon","year":"2011","unstructured":"Doyon S. Anticonvulsants. In: Nelson LS, Howland MA, Lewin NA, Flomenbaum NE, Hoffman RS, Goldfrank LR, editors. Goldfrank\u2019s toxicologic emergencies. 9th ed. New York (NY): McGraw-Hill; 2011. p. 698\u2013706.","edition":"9th ed"},{"issue":"13-14","key":"1024_CR28","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.clinbiochem.2015.05.014","volume":"48","author":"I Burianov\u00e1","year":"2015","unstructured":"Burianov\u00e1 I, Bo\u0159eck\u00e1 K. Routine therapeutic monitoring of the active metabolite of carbamazepine: is it really necessary? Clin Biochem. 2015;48(13\u201314):866\u20139. https:\/\/doi.org\/10.1016\/j.clinbiochem.2015.05.014.","journal-title":"Clin Biochem"},{"key":"1024_CR29","doi-asserted-by":"publisher","DOI":"10.3109\/9781420044805","volume-title":"Poisoning and toxicology handbook","author":"JB Leikin","year":"2007","unstructured":"Leikin JB, Paloucek FP. Poisoning and toxicology handbook. 4th ed. New York (NY): Informa Healthcare; 2007.","edition":"4th ed"},{"issue":"9","key":"1024_CR30","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/clinchem\/38.9.1853","volume":"38","author":"TA Manolio","year":"1992","unstructured":"Manolio TA, Burke GL, Savage PJ, Jacobs DR Jr, Sidney S, Wagenknecht LE, et al. Sex- and race-related differences in liver-associated serum chemistry tests in young adults in the CARDIA study. Clin Chem. 1992;38(9):1853\u20139.","journal-title":"Clin Chem"},{"issue":"3","key":"1024_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/00007691-198609000-00011","volume":"8","author":"TB Vree","year":"1986","unstructured":"Vree TB, Janssen TJ, Hekster YA, Termond EF, van de Dries AC, Wijnands WJ. Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose. Ther Drug Monit. 1986;8(3):297\u2013304. https:\/\/doi.org\/10.1097\/00007691-198609000-00011.","journal-title":"Ther Drug Monit."},{"issue":"3","key":"1024_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/096032718700600312","volume":"6","author":"PN Patsalos","year":"1987","unstructured":"Patsalos PN, Krishna S, Elyas AA, Lascelles PT. Carbamazepine and carbamazepine-10,11-epoxide pharmacokinetics in an overdose patient. Hum Toxicol. 1987;6(3):241\u20134. https:\/\/doi.org\/10.1177\/096032718700600312.","journal-title":"Hum Toxicol"},{"issue":"5","key":"1024_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/BF00878554","volume":"9","author":"G Kenneb\u00e4ck","year":"1995","unstructured":"Kenneb\u00e4ck G, Bergfeldt L, Tomson T. Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects. Cardiovasc Drugs Ther. 1995;9(5):709\u201314. https:\/\/doi.org\/10.1007\/BF00878554.","journal-title":"Cardiovasc Drugs Ther."},{"issue":"6","key":"1024_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1081\/clt-120015836","volume":"40","author":"RI Winnicka","year":"2002","unstructured":"Winnicka RI, Topaci\u0144ski B, Szymczak WM, Szyma\u0144ska B. Carbamazepine poisoning: elimination kinetics and quantitative relationship with carbamazepine 10,11-epoxide. J Toxicol Clin Toxicol. 2002;40(6):759\u201365. https:\/\/doi.org\/10.1081\/clt-120015836.","journal-title":"J Toxicol Clin Toxicol."},{"issue":"4","key":"1024_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3109\/15563659009038587","volume":"28","author":"HA Spiller","year":"1990","unstructured":"Spiller HA, Krenzelok EP, Cookson E. Carbamazepine overdose: a prospective study of serum levels and toxicity. J Toxicol Clin Toxicol. 1990;28(4):445\u201358. https:\/\/doi.org\/10.3109\/15563659009038587.","journal-title":"J Toxicol Clin Toxicol."},{"issue":"5","key":"1024_CR36","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1212\/wnl.31.5.621","volume":"31","author":"JB Sullivan Jr","year":"1981","unstructured":"Sullivan JB Jr, Rumack BH, Peterson RG. Acute carbamazepine toxicity resulting from overdose. Neurology. 1981;31(5):621\u20134. https:\/\/doi.org\/10.1212\/wnl.31.5.621.","journal-title":"Neurology"},{"issue":"1","key":"1024_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-020-00425-2","volume":"21","author":"A Hirsch","year":"2020","unstructured":"Hirsch A, Wanounou M, Perlman A, Hirsh-Raccah B, Muszkat M. The effect of multidrug exposure on neurological manifestations in carbamazepine intoxication: a nested case-control study. BMC Pharmacol Toxicol. 2020;21(1):47. https:\/\/doi.org\/10.1186\/s40360-020-00425-2.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"1024_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.toxac.2024.11.012","volume":"37","author":"S Madhbouh","year":"2025","unstructured":"Madhbouh S, Jeddi C, Kilani M, Thabet H. Acute carbamazepine poisoning: correlation between clinical findings and serum levels. Toxicol Anal Clin. 2025;37(2):186\u201393. https:\/\/doi.org\/10.1016\/j.toxac.2024.11.012.","journal-title":"Toxicol Anal Clin"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01024-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01024-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01024-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:52:57Z","timestamp":1786704777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01024-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":38,"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01024-y","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Momir Mikov is an Editorial Board member of the European Journal of Drug Metabolism and Pharmacokinetics. Momir Mikov was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.\u00a0All other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because this retrospective study uses anonymised data, the Ethics Committee waived the requirement for individual informed consent.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. All data were fully anonymised prior to analysis, and no individually identifiable patient information was reported.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Military Medical Academy (Approval No. 18\/2022, dated June 1, 2022). All procedures were conducted in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}